Clinical trial
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
NCT00003076 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003076 |
|---|---|
| Title | Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus |
| Official title | Phase IIb Chemoprevention Trial of Difluoromethylornithine (DFMO) in Human Subjects With Intestinal-type Barrett's Esophagus |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug |
| Interventions | eflornithine |
| Enrollment | 152 |
| Start date | Oct 1, 1995 |
| Primary completion | Jun 1, 2002 |
| Completion | Oct 1, 2005 |
| First posted | Apr 23, 2004 |
| Last update posted | Dec 19, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: